EHA 2021 Top Pick #2: Minimal Residual Disease Driven Treatment Intensification with Sequential Addition of Ibrutinib (IBR) to Venetoclax (VEN) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): The Improve Study

You are here: